CAS NO: | 1051375-19-9 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 441.36 |
---|---|
Formula | C20H19F2N3O5.Na |
CAS No. | 1051375-19-9 (sodium); |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: >4.4 mg/mL; < 12.6 mg/mL |
Water: <1 mg/mL | |
Ethanol:<1 mg/mL | |
SMILES | O=C(C1=CN(C2=C(O)C1=O)C[C@]3([H])OCC[C@@H](C)N3C2=O)[N-]CC4=CC=C(F)C=C4F.[Na+] |
Synonyms | GSK-1349572A; GSK1349572 sodium; GSK-1349572 sodium; GSK 1349572 sodium; Dolutegravir Sodium |
In Vitro | In vitro activity: Dolutegravir(S/GSK1349572) inhibits HIV-1 integrase-catalyzed strand transfer with a 50% inhibitory concentration (IC50) of 2.7 nM. S/GSK1349572 inhibits both the HIV integration reaction strand transfer step in vitro and HIV replication in cells with similar potencies. The inhibitor has no effect on total viral DNA synthesis in infected cells but blocks the integration of viral DNA into host DNA with the same potency as its antiviral effect. Kinase Assay: The inhibitory potencies of S/GSK1349572 and other INIs are measured in a strand transfer assay using recombinant HIV integrase. A complex of integrase and biotinylated preprocessed donor DNA-streptavidin-coated Acintillation proximity assay (SPA) beads is formed by incubating 2 μM purified recombinant integrase with 0.66 μM biotinylated donor DNA-4 mg/mL streptavidin-coated SPA beads in 25 mM sodium morpholinepropanesulfonic acid (MOPS) (pH 7.2), 23 mM NaCl, and 10 mM MgCl2 for 5 minutes at 37 °C. These beads are spun down and preincubated with diluted INIs for 60 minutes at 37 °C. Then a 3H-labeled target DNA substrate is added to give a final concentration of 7 nM substrate, and the strand transfer reaction mixture is incubated at 37 °C for 25 to 45 minutes, which allows for a linear increase in the strand transfer of donor DNA to radiolabeled target DNA. The signal is read using a Wallac MicroBeta scintillation plate reader. Cell Assay: MT-4 cells growing exponentially at a density of 500000 or 600000 /mL are infected with HIV-1 strain IIIB at a viral multiplicity of infection of 0.001 or a 50% tissue culture infective dose of 4 to 10. The cells are then aliquoted to 96-well plates in the presence of varying concentrations of S/GSK1349572. After incubation for 4 or 5 days, antiviral activity is determined by a cell viability assay that either measured bioluminescence with a CellTiter-Glo luminescent reagent or measured absorbance at 560 and 690 nm using the yellow tetrazolium MTT reagent [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide]. |
---|---|
In Vivo | The bioavailability of dolutegravir was high when administered as a solution, but was limited by dissolution rate or solubility when administered as a suspension. Dolutegravir is the major circulating component in mice, rats, and monkeys, with direct ether glucuronidation shown to be the primary biotransformation pathway. Dolutegravir is primarily eliminated via the feces either unabsorbed or by hydrolysis of the glucuronide or glucose conjugate. |
Animal model | male Crl:CD (SD) rats, cynomolgus monkeys |
Formulation & Dosage | Formulated as a solution in N,N-dimethylacetamide and diluted with 50 Mm N-methylglucamine in 3% mannitol; mg/kg for i.v.; 5, 50, 100, and 250 mg/kg(rats, oral); 3, 10, and 50 mg/kg(monkeys, oral); oral or i.v. |
References | AIDS. 2010 Nov 13;24(17):2753-5; Antimicrob Agents Chemother. 2011 Feb;55(2):813-21; Antivir Chem Chemother. 2015 Apr;24(2):72-6; Xenobiotica. 2015 Jan;45(1):60-70. |